Bioxyne Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingredients and starting materials; plant-based food products, such as non-controlled cannabis extracts and cannabidiol; food grade mushroom extracts/psilocybin; medicinal and prescription cannabis products, including pastilles, vape, oral mucosal oils, flower, and suppositories; SL-NAD+ wafers; MDMA; white label manufactured wellness products; health and wellness supplements; and nootropic and skincare products. It also provides Lactobacillus fermentum VRI-003 PCC, a probiotic formulation for gastrointestinal health and immunity; Progastrim for gut and immune health; and proTract for atopic dermatitis. In addition, the company is involved in the contract manufacturing of final dose form products, including capsules, tablets, inhalables, oral solutions, and herbal preparations; import, export, manufacture, and supply of controlled drugs and medicinal products; research and development of formulations, products, and processes related to health, wellness, and medicine; and provision of telemedicine services. Further, it operates CanXChange, a machine-learning powered B2B wholesale and custody technology platform. The company offers its products to cultivators, manufacturers, pharmacies, clinics, and patients under the Breathe Life Science, Dr Watson, Mirai Solution, and Apothecary CBD brands. It sells its products through wholesale, retail, and online. Bioxyne Limited is headquartered in Sydney, Australia.
Key Metrics
PE ratio
Infinity
PB ratio
6.67
Dividend yield
-
Beta
0.54
Market cap
$89.60M
Enterprise value
$80.43M
Company profile
| Industry / Sector | Packaged Foods / Consumer Defensive |
|---|---|
| Website | https://bioxyne.com |
| Mailing address | 50 Clarence Street Suite 506, Level 5 Sydney NSW 2000 Australia |
| Phone / Fax | 61 2 9078 8180 / 61 2 9078 7661 |
Dividends
More: Bioxyne Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Bioxyne paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.BXN dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Bioxyne.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Samuel Watson | CEO, MD & Executive Director | ||
| Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD | CFO & Company Secretary | 72 | |
| Mr. Jason Hine | COO & Executive Director | ||
| Macdarragh O'Neill | Head of Production of GMP & Director of BLS Wholesalers Pty |
Profitability and management effectiveness
Profit margin
16.74%
Operating margin
8.98%
Return on assets
24.26%
Return on equity
63.64%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Bioxyne is 89.60M and its enterprise value is 80.43M. The enterprise value to revenue ratio of BXN is 2.75. The enterprise value to EBITDA ratio of BXN is 14.89.
The BXN's stocks Beta value is 0.54 making it 46% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Bioxyne (BXN)
Bioxyne (ASX:BXN) Frequently Asked Questions
1. What is Bioxyne's Stock Symbol?
Bioxyne trades on ASX under the ticker symbol "BXN".
2. What is Bioxyne's stock price today?
One share of BXN stock can currently be purchased for approximately $0.04.
3. How can I contact Bioxyne?
Bioxyne's mailing address is 50 Clarence Street Suite 506, Level 5 Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 9078 8180.
4. What is Bioxyne's official website?
The official website of Bioxyne is https://bioxyne.com.